Real-time HTA tracking and AI-powered PICO simulation equip launch and brand teams with faster, more strategic HTA insights.
LONDON, UK – Tuesday 3rd March 2026 – Access Infinity today announced significant enhancements to Nuro™, its market access insights platform, at this year’s World EPA Congress. The new capabilities, HTA Tracking and PICO Simulation, are designed to help launch, brand and indication leaders stay ahead of evolving HTA dynamics and prepare strategically for the European Joint Clinical Assessment (JCA) process.
Across Europe, HTA decisions, restrictions and payer expectations continue to evolve rapidly, particularly as the JCA framework is implemented. Many organisations still rely on periodic PowerPoint reports from external vendors, often costing in excess of £500,000 annually and becoming outdated long before the next reporting cycle.
Commenting on the announcement, Thomas Gilboy, Product Owner at Access Infinity said:
Nuro HTA Tracking provides detailed insight across a defined competitive set, updated in near real-time. Teams can monitor HTA outcomes and restrictions across Europe, analyse key decision drivers and identify emerging payer patterns without relying on static reporting cycles.
Nuro PICO Simulation supports JCA preparation by analysing clinical guidelines and historical HTA assessments to identify likely populations, comparators and outcomes. By highlighting the elements most frequently assessed across countries, the tool enables teams to prioritise evidence generation and refine strategy earlier in the development cycle.
The Access Infinity team is showcasing Nuro at World EPA Congress, 3–4 March. Visit Stand 204 to learn more or arrange a dedicated discussion with us: accessinfinity.com/see-nuro-in-action-access-infinity
About Access Infinity
Founded in 2014, Access Infinity helps pharmaceutical companies launch and price their products more effectively by combining deep strategic consulting expertise with digital platforms purpose-built for market access and HEOR teams. The company’s experienced consultants work closely with global through to local teams to shape launch strategies, optimise pricing and access, and navigate complex policy landscapes.
Access Infinity’s core digital solutions – Access Hub, Evidence Hub and Nuro – streamline everything from launch tracking and evidence planning to pricing strategy, enabling faster, smarter, and more coordinated decision-making across the product lifecycle. With offices in London, Manchester and Hyderabad, Access Infinity’s clients include many of the pharmaceutical industry’s most influential companies including AstraZeneca, GSK, J&J, MSD, and Pfizer.
For media enquiries, please contact:
Email: louise@accessinfinity.com
Tel: +44 (0)20 4583 5450
